Overall rank by patents
#26,019
Across all tracked assignees
USPTO PatentsView assignee record - 10 granted patents across 4 technology areas, active 2015–2021. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: H01L (SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10).
The verdict
Carsem holds 10 US patents across 4 technology areas, rank #26,019 of 50,000 tracked assignees.
Carsem (m) SDN. BHD. has been granted 10 US utility patents between 2015 and 2021, placing Carsem (m) SDN. BHD. at rank #26,019 across all assignees tracked by PlainPatent. This portfolio spans 4 distinct Cooperative Patent Classification (CPC) subclasses, averaging 16.2 claims per patent with primary concentration in H01L (SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10). As a Foreign Corporation, Carsem (m) SDN. BHD. is one of the more focused assignees in the PatentsView dataset. By volume, Carsem sits between Capitalogix IP Owner, Llc (10 patents, rank #26,015) and Cellucomp Limited (10 patents, rank #26,023) - the closest US assignees by grant volume. The composite Innovation Score of 25.1/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 1 grants, compared with 9 in the 2015–2019 window, a -89% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Carsem (m) SDN. BHD.'s 16.2 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while specialization in 4 subclasses reflects a tightly scoped invention area. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Carsem (m) SDN. BHD. against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
Capitalogix IP Owner, LLC
10 patents
Captricity, Inc.
10 patents
Carna Biosciences, Inc.
10 patents
Carr Lane Manufacturing Company
10 patents
Casabella Holdings, L.L.C.
10 patents
Cave Consulting Group, Inc.
10 patents
CeMM—Forschungszentrum für Molekulare Medizin GmbH
10 patents
CelluComp Limited
10 patents
Carsem (M) SDN. BHD.
10 patents
What this shows Carsem holds 10 patents at rank #26,019, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Carsem's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
25 Top 84% higher than 16% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 4 | 40.0% |
| 2017 | 2 | 20.0% |
| 2018 | 2 | 20.0% |
| 2019 | 1 | 10.0% |
| 2021 | 1 | 10.0% |
Top 4 of 4 technology areas
Overall rank by patents
#26,019
Across all tracked assignees
25.1 out of 100
How to use this portfolio
Carsem's 10 grants land it in the top 84% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.